logo
Twitter
Discord
Email
logo
Haleon plc

Haleon plc

NYSE•HLN
CEO: Mr. Brian James McNamara
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Contact Information
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
www.haleon.com
Market Cap
$42.88B
P/E (TTM)
21.2
80.9
Dividend Yield
1.6%
52W High
$11.42
52W Low
$8.71
52W Range
28%
Rank38Top 27.7%
4.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Average • 4.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q2 2025 Data

Revenue

$7.33B+97.48%
4-Quarter Trend

EPS

$0.24+172.73%
4-Quarter Trend

FCF

$1.25B+0.00%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Organic Revenue Growth Strong Organic revenue grew 5.0% for 2024; reported revenue declined (0.6)% to £11.2bn due to FX headwinds.
Profitability and Margin Expansion Operating profit reached £2.2bn, up 10.5% reported; adjusted operating margin grew 100bps organically to 22.3%.
Deleveraging and Shareholder Returns Returned over £1bn to shareholders via buybacks and dividends; Net debt/adjusted EBITDA reduced to 2.8x.
Health Inclusivity Target Achieved Empowered over 50m people against health inclusivity goal, achieving the 2025 target one year ahead of plan.

Risk Factors

FX Headwinds Impact Reported Revenue Adverse foreign exchange movements caused £421m negative impact on reported revenue decline of (0.6)%.
Increased Cyber Security Threat Profile Cyber security risk increased due to rising sophistication of threats, third-party exposure, and new risks from AI adoption.
Geopolitical Instability Risk Rises Geopolitical instability risk increased reflecting ongoing conflicts and rising protectionism impacting global operations and talent movement.
Supply Chain Resilience Tested Global sourcing network faces disruption from geopolitical instability, extreme weather, and commodity volatility impacting service levels.

Outlook

Medium-Term Revenue Guidance Medium-term guidance targets annual organic revenue growth between 4-6% supported by portfolio strength.
2025 Profit Growth Ahead Expecting 2025 organic revenue growth of 4-6%, with organic operating profit growth anticipated to be ahead of revenue.
Continued Capital Allocation Discipline Board approved £500m capital allocation for share buybacks in 2025, balancing investment and shareholder returns.
Evolving Strategy and Culture Priorities for 2025 include continued transformation into agile business and evolving culture to capitalize on opportunities.

Peer Comparison

Revenue (TTM)

Cardinal Health, Inc.CAH
$234.31B
+4.5%
Humana Inc.HUM
$126.36B
+9.9%
Takeda Pharmaceutical Company LimitedTAK
$29.67B
-2.8%

Gross Margin (Latest Quarter)

Edwards Lifesciences CorporationEW
77.9%
-2.7pp
Zoetis Inc.ZTS
71.5%
+2.4pp
Takeda Pharmaceutical Company LimitedTAK
65.8%
-0.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ZTS$52.03B19.753.6%1.3%
EW$49.27B36.013.4%5.3%
CAH$47.09B29.6-55.0%16.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
26.6%
Strong Growth
4Q Net Income CAGR
19.6%
Profitability Improved
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 20, 2025|
    Revenue: $14.35B-0.6%
    |
    EPS: $0.41+33.3%
    Beat

  • Form 20-F/A - FY 2023

    Period End: Dec 31, 2023|Filed: May 24, 2024|
    Revenue: $14.36B+4.1%
    |
    EPS: $0.30+0.0%
    Beat

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 15, 2024|Refer to amended data

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 20, 2023|
    Revenue: $13.38B+13.8%
    |
    EPS: $0.30-20.0%
    Miss